Alexinib is an oral drug used to treat some forms of lung cancer. It primarily targets non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive and is a member of the class of medications known as tyrosine kinase inhibitors (TKIs). By inhibiting the ALK protein, it helps stop cancer cells from growing and spreading.

There are 150 milligrams of alexinib, the active ingredient, in each capsule. It is typically used when other treatments, including crizotinib, have not worked or when the illness has progressed to other areas of the body.

Uses

Alectinib is primarily used to treat:

Non-small cell lung cancer (NSCLC) that is ALK-positive in patients whose disease has progressed to other organs. It is only for patients who have undergone an FDA-approved test and tested positive for the ALK gene mutation. When earlier ALK inhibitors, such crizotinib, have failed, this medication is frequently employed.

Dosage

The recommended dosage of Alectinib is:

Adults typically take 600 mg twice a day with food, which is equivalent to four 150 mg capsules.
The total daily dosage, split into two doses, is 1200 mg.
The patient’s reaction, adverse effects, or liver function may all influence the dosage.
Unless the next planned dose is approaching, any missing doses should be taken as soon as possible.

Dosage Adjustments

The doctor may reduce the dosage if there are liver issues. In the event of severe side effects, the medication may be temporarily discontinued or the dosage may be lowered. There is no need to modify the dosage in cases with kidney illness. The capsules should be consumed whole with water; do not chew, crush, or open them.

Side Effects

Alectinib may cause some side effects. These can be common or serious, requiring medical attention.

Common Side Effects
Exhaustion and constipation
Feeling queasy
Having diarrhea
Hands, feet, or face swelling
Weakness or discomfort in the muscles
Serious Adverse Reactions
Liver issues include dark urine, nausea, abdominal pain, and yellowing of the skin or eyes.
Pneumonitis-related lung inflammation (cough, dyspnea, fever)
severe myopathy, or muscle damage, which manifests as weakness and inexplicable agony.
Heart issues (dizziness, fainting, sluggish heartbeat)
Extreme sun sensitivity, as seen by blistering and redness when exposed to sunlight
Seek medical help right away if there are any serious reactions.

Storage

Store between 20°C and 25°C (68°F and 77°F) at room temperature. Store away from heat and moisture in a dry location. Keep out of the direct sun. Keep the medication properly sealed in its original container. Keep out of children’s and pets’ reach.

Precautions

Breastfeeding with pregnancy: Not advised during pregnancy as it may be harmful to the unborn child. When taking Alectinib and for at least a week following the last dosage, women should use contraception. Liver Monitoring: It is necessary to perform routine liver function testing. Sun Protection: Apply sunscreen with an SPF of 50 or higher and stay out of direct sunlight. Steer clear of grapefruit since it may increase the likelihood of adverse effects.

Conclusion

Alexinib 150 mg is a successful treatment for ALK-positive non-small cell lung cancer in patients whose disease has progressed or who have not responded to prior therapies. There are some potential problems and safety precautions that should be carefully considered, even though it is encouraging to many. Always use alexinib exactly as prescribed by your physician, and contact them if you have any questions or experience any unusual side effects.

Buy Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

Q. How much time can someone with stage 4 NSCLC live?

The majority of patients with stage IV nonsmall cell lung cancer (NSCLC) globally have a poor prognosis; between 25% and 30% pass away within three months. However, 10% to 15% of those who survive longer than three months (70,000 to 105,000 new patients annually worldwide) survive (very) long.

Q. Chemotherapy ages you by how many years?

Although the long-term therapeutic significance of this reduction is unknown, short-term chemotherapy may result in the equivalent of ten years of physiological aging because VO2peak normally decreases by 10% every ten years in healthy women.